After numerous large randomised trials, it is now broadly admitted by the entire cardiology community that at least 12 months’ dual antiplatelet therapy (DAPT) with a P2Y12 receptor inhibitor in combination with aspirin is recommended in patients with acute coronary syndromes (ACS) managed by coronary stent implantation, except in case of a high risk of bleeding1. The ultimate goal of longer rather than shorter DAPT is to prevent thrombus formation in future plaque rupture in patients with a history of ACS, who are at greater risk of ischaemic events than those without, mostly due to plaque destabilisation2. In ACS ...